Literature DB >> 13679438

Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1.

James Thompson1, Katriina J Peltola, Päivi J Koskinen, Olli A Jänne, Jorma J Palvimo.   

Abstract

Androgens play a key role in the regulation of the normal prostate as well as in the promotion and progression of prostate cancer. Recently, an oncogenic serine/threonine kinase, Pim-1, was reported to be overexpressed in prostate cancer. To elucidate whether Pim-1 is capable of modulating androgen signaling, we studied the effects of Pim-1 on androgen receptor (AR)-dependent transcription. Under transient transfection conditions, Pim-1 attenuated transcriptional activity of AR in a dose-dependent fashion in PC-3, HeLa, and COS-1 cells, whereas a kinase-negative mutant of Pim-1, Pim-1(K67M), showed no repressive activity. In contrast, ectopic expression of Pim-1 did not influence the activity of endogenous AR in LNCaP cells. This was, however, not a result of the T877A mutation present in AR of LNCaP cells, because that AR mutant was repressed by Pim-1 as efficiently as wild-type AR when expressed in PC-3 prostate cancer cells. Pim-1 inhibited AR mutants devoid of the ligand-binding domain or the core amino-terminal transactivation function but failed to influence the DNA binding of AR. Because we found no evidence for phosphorylation of AR by Pim-1 or for direct interaction between these proteins, Pim-1 is likely to influence AR activity via an indirect mechanism, possibly involving phosphorylation of a coregulator and/or a component of the transcription machinery. Overexpression of Pim-1 may thus attenuate androgen response during progression of prostate cancer in a cell context-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679438     DOI: 10.1097/01.lab.0000087585.03162.a3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

1.  Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription.

Authors:  James Thompson; Tatyana Lepikhova; Neus Teixido-Travesa; Maria A Whitehead; Jorma J Palvimo; Olli A Jänne
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

Review 2.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

3.  Overexpression of Pim-1 during progression of prostatic adenocarcinoma.

Authors:  T L Cibull; T D Jones; L Li; J N Eble; L Ann Baldridge; S R Malott; Y Luo; L Cheng
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

4.  Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Authors:  Jongchan Kim; Meejeon Roh; Sarki A Abdulkadir
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

5.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Authors:  Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

6.  PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling.

Authors:  Christina J Maier; Richard H Maier; Raphaela Rid; Andrea Trost; Harald Hundsberger; Andreas Eger; Helmut Hintner; Johann W Bauer; Kamil Onder
Journal:  BMC Mol Biol       Date:  2012-06-21       Impact factor: 2.946

7.  Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Authors:  S Ha; N J Iqbal; P Mita; R Ruoff; W L Gerald; H Lepor; S S Taneja; P Lee; J Melamed; M J Garabedian; S K Logan
Journal:  Oncogene       Date:  2012-09-17       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.